These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 3653246)

  • 1. Central cholecystokinin octapeptide reduces glucose utilization in subcortical but not cortical rat brain.
    Tamminga CA; Tanimoto K; Kuo S; Beck M; Chase TN
    Eur J Pharmacol; 1987 Jul; 139(2):237-41. PubMed ID: 3653246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of systemically administered cholecystokinin-octapeptide on local cerebral metabolism.
    Lucignani G; Porrino LJ; Tamminga CA
    Eur J Pharmacol; 1984 May; 101(1-2):147-51. PubMed ID: 6086359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin and an evoked response in the dentate gyrus.
    Sinton CM
    Neuropeptides; 1988 Jul; 12(1):29-34. PubMed ID: 3419558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversed behavioral effect of cholecystokinin after frontal decortication in rats.
    Itoh S; Katsuura G; Itoh T; Morimoto T
    Life Sci; 1994; 55(11):PL213-6. PubMed ID: 8072383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cholecystokinin on acetylcholine turnover and dopamine release in the rat striatum and cortex.
    Cosi C; Altar AC; Wood PL
    Eur J Pharmacol; 1989 Jun; 165(2-3):209-14. PubMed ID: 2776829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of cholecystokinin octapeptide (CCK-8) in regulating thyrotropin secretion in rats. In vivo studies].
    Krowicki ZK; Sadowska-Krowicka H
    Endokrynol Pol; 1989; 40(3):133-41. PubMed ID: 2627920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic intraventricular administration of cholecystokinin octapeptide (CCK-8) suppresses feeding in rats.
    Schick RR; Stevens CW; Yaksh TL; Go VL
    Brain Res; 1988 May; 448(2):294-8. PubMed ID: 3378151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of food intake by central administration of cholecystokinin octapeptide in the rat is dependent upon inhibition of brain peptidases.
    Griesbacher T; Leighton GE; Hill RG; Hughes J
    Br J Pharmacol; 1989 Jan; 96(1):236-42. PubMed ID: 2647203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cholecystokinin octapeptide on genetically determined seizure susceptibility.
    Wu XR; Lin PX
    Chin Med J (Engl); 1992 Feb; 105(2):110-5. PubMed ID: 1597069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fronto-cortical regulation of beta-endorphin actions in the rat.
    Itoh S; Katsuura G
    Peptides; 1985; 6(2):237-40. PubMed ID: 3162160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of cholecystokinin-induced increase in acetylcholine output from cerebral cortex of the rat.
    Magnani M; Florian A; Casamenti F; Pepeu G
    Neuropharmacology; 1987 Aug; 26(8):1207-10. PubMed ID: 3658123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulphated cholecystokinin octapeptide inhibits ethanol consumption in the rat.
    Kulkosky PJ; Chavez MR
    Alcohol; 1984; 1(5):409-12. PubMed ID: 6100357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral effect of cholecystokinin octapeptide in vagotomized rats.
    Itoh S; Katsuura G
    Can J Physiol Pharmacol; 1986 Jun; 64(6):745-7. PubMed ID: 3756626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further analysis of the effects of cholecystokinin octapeptides on avoidance behaviour in rats.
    Fekete M; Lengyel A; Hegedüs B; Penke B; Zarándy M; Tóth G; Telegdy G
    Eur J Pharmacol; 1984 Feb; 98(1):79-91. PubMed ID: 6325212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism.
    Crawley JN; Fiske SM; Durieux C; Derrien M; Roques BP
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1076-80. PubMed ID: 2046021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary.
    Millington WR; Mueller GP; Lavigne GJ
    J Pharmacol Exp Ther; 1992 May; 261(2):454-61. PubMed ID: 1578360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of cholecystokinin octapeptide on ethanol-induced changes in motor activity and in dopamine metabolism in the nucleus accumbens of the rat brain].
    Medvedeva OF; Sudakova SK; Anokhina IP; Kianmaa K
    Eksp Klin Farmakol; 1996; 59(6):44-7. PubMed ID: 9181874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proglumide has access to brain and antagonizes the central satiety effect of cholecystokinin octapeptide in the dog.
    Inui A; Inoue T; Sakatani N; Oya M; Morioka H; Baba S
    Brain Res; 1987 Aug; 417(2):355-9. PubMed ID: 3651819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intraventricular administration of cholecystokinin octapeptide sulfate ester and unsulfated cholecystokinin octapeptide on active avoidance and conditioned feeding behaviour of rats.
    Fekete M; Szabó A; Balázs M; Penke B; Telegdy G
    Acta Physiol Acad Sci Hung; 1981; 58(1):39-45. PubMed ID: 6282048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.